Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert

In Europe, prostate cancer is the most common cancer among men with 382.000 new cases and 89.000 deaths annually. Historically, androgen deprivation therapy and docetaxel based chemotherapy were the only treatments able to improve survival. Two studies have been published during last few months rega...

Full description

Bibliographic Details
Main Authors: Amelia Altavilla, Roberto Iacovelli, Giuseppe Procopio, Enrico Cortesi
Format: Article
Language:English
Published: SAGE Publishing 2012-06-01
Series:Therapeutic Advances in Urology
Online Access:https://doi.org/10.1177/1756287212440302